1
|
Qu Y, Wang J, Chen Y, Xiao S, He Y, Zhang N, Zheng H, Liu Q, Liu H. Establishment and application of a wild neonatal mouse model infected with an Echovirus 30 isolate. Virol J 2025; 22:69. [PMID: 40075457 PMCID: PMC11899154 DOI: 10.1186/s12985-025-02684-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2024] [Accepted: 02/26/2025] [Indexed: 03/14/2025] Open
Abstract
BACKGROUND Echovirus 30 (E30) is a significant pathogen associated with various illnesses such as viral meningitis, viral myocarditis. Currently, there are no specific drugs or vaccines targeting this virus. An appropriate animal model is imperative for assessing drug and vaccine efficacy. METHODS This investigation aimed to establish a neonatal mouse model using a clinical isolate E30/A538 and apply it to screen anti-E30 drugs. The study involved evaluating the susceptibility of different mouse strains to the isolate, determining the infectious dose, transmission route, and optimal age of the mice. This model was then used to assess antiviral efficacy. RESULTS Neonatal ICR mice infected intracranially with 5LD50 of E30/A538 at one-day-old displayed clinical symptoms such as tremors, lethargy, limb paralysis, and mortality. Importantly, the E30/A538-infected mice exhibited brain neuron apoptosis and severe myocardial necrolysis, closely resembling human infections. Elevated levels of viral RNA and positive antigen presence were predominantly detected in the brains and hearts of infected mice. Using this model to assess antiviral efficacy, it was demonstrated that interferon-α2a inhibited E30/A538 replication in vivo, mitigated histopathological changes in the brain, spinal cord, and myocardium, and enhanced the survival rate of neonatal mice. CONCLUSIONS In summary, this research established a wild neonatal mouse model of E30/A538 isolate infection that mirrors the characteristics of human infection. The model demonstrated the efficacy of interferon-α2a in combating E30. This model would serve as a foundation for investigating the pathogenesis of E30, as well as for assessing the efficacy of vaccines and other antiviral treatments against E30.
Collapse
Affiliation(s)
- Ying Qu
- Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, China
- College of Pharmacy, Guilin Medical University, Guilin, Guangxi, China
| | - Jing Wang
- Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, China
- College of Pharmacy, Guilin Medical University, Guilin, Guangxi, China
| | - Yongbei Chen
- Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, China
- Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, Guangxi Clinical Research Center for Diabetes and Metabolic Diseases, Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, China
| | - Shengjun Xiao
- Department of Pathology, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China
| | - Yunyi He
- College of Laboratory Medicine, Guilin Medical University, Guilin, Guangxi, China
| | - Ning Zhang
- Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, China
- Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, Guangxi Clinical Research Center for Diabetes and Metabolic Diseases, Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, China
| | - Huanying Zheng
- Guangdong Provincial Institute of Public Health, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China.
| | - Qiliang Liu
- Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, China.
- College of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin, Guangxi, China.
- Key Laboratory of Medical Biotechnology and Translational Medicine, Education Department of Guangxi Zhuang Autonomous, Nanning, China.
| | - Hongbo Liu
- Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, China.
- Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, Guangxi Clinical Research Center for Diabetes and Metabolic Diseases, Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, China.
- College of Laboratory Medicine, Guilin Medical University, Guilin, Guangxi, China.
| |
Collapse
|
2
|
Brisca G, Bellini T, Pasquinucci M, Mariani M, Romanengo M, Buffoni I, Tortora D, Parodi A, Fueri E, Mesini A, Tibaldi J, Piccotti E, Ramenghi LA, Moscatelli A. Clinical course and peculiarities of Parechovirus and Enterovirus central nervous system infections in newborns: a single-center experience. Eur J Pediatr 2024; 183:2615-2623. [PMID: 38492030 DOI: 10.1007/s00431-024-05518-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2024] [Revised: 03/04/2024] [Accepted: 03/09/2024] [Indexed: 03/18/2024]
Abstract
Parechovirus (HpEV) and Enterovirus (EV) infections in children mostly have a mild course but are particularly fearsome in newborns in whom they may cause aseptic meningitis, encephalitis, and myocarditis. Our study aimed to describe the clinical presentations and peculiarities of CNS infection by HpEV and EV in neonates. This is a single-center retrospective study at Istituto Gaslini, Genoa, Italy. Infants aged ≤ 30 days with a CSF RTq-PCR positive for EV or HpEV from January 1, 2022, to December 1, 2023, were enrolled. Each patient's record included demographic data, blood and CSF tests, brain MRI, therapies, length of stay, ICU admission, complications, and mortality. The two groups were compared to identify any differences and similarities. Twenty-five patients (15 EV and 10 HpEV) with a median age of 15 days were included. EV patients had a more frequent history of prematurity/neonatal respiratory distress syndrome (p = 0.021), more respiratory symptoms on admission (p = 0.012), and higher C-reactive protein (CRP) levels (p = 0.027), whereas ferritin values were significantly increased in HpEV patients (p = 0.001). Eight patients had a pathological brain MRI, equally distributed between the two groups. Three EV patients developed myocarditis and one HpEV necrotizing enterocolitis with HLH-like. No deaths occurred. Conclusion: EV and HpEV CNS infections are not easily distinguishable by clinical features. In both cases, brain MRI abnormalities are not uncommon, and a severe course of the disease is possible. Hyper-ferritinemia may represent an additional diagnostic clue for HpEV infection, and its monitoring is recommended to intercept HLH early and initiate immunomodulatory treatment. Larger studies are needed to confirm our findings. What is Known: • Parechovirus and Enteroviruses are the most common viral pathogens responsible for sepsis and meningoencephalitis in neonates and young infants. • The clinical course and distinguishing features of Parechovirus and Enterovirus central nervous system infections are not well described. What is New: • Severe disease course, brain MRI abnormalities, and complications are not uncommon in newborns with Parechovirus and Enteroviruses central nervous system infections. • Hyper-ferritinemia may represent an additional diagnostic clue for Parechovirus infection and its monitoring is recommended.
Collapse
Affiliation(s)
- Giacomo Brisca
- Neonatal and Pediatric Intensive Care Unit, and Intermediate Care Unit, Emergency Department, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genoa, Italy.
| | - Tommaso Bellini
- Emergency Room and Pediatric Emergency Medicine Unit, Emergency Department, IRCCS Istituto Giannina Gaslini, Genoa, Italy
| | - Mattia Pasquinucci
- Department of Neurosciences, Genetics and Maternal and Child Health (DINOGMI), University of Genova, RehabilitationGenoa, Ophthalmology, Italy
| | - Marcello Mariani
- Pediatric Infectious Diseases Unit, Department of Pediatrics, IRCCS Istituto Giannina Gaslini, Genoa, Italy
| | - Marta Romanengo
- Neonatal and Pediatric Intensive Care Unit, and Intermediate Care Unit, Emergency Department, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genoa, Italy
| | - Isabella Buffoni
- Neonatal and Pediatric Intensive Care Unit, and Intermediate Care Unit, Emergency Department, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genoa, Italy
| | - Domenico Tortora
- Neuroradiology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy
| | - Alessandro Parodi
- Department Mother and Child, Neonatal Intensive Care Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy
| | - Elena Fueri
- Department of Neurosciences, Genetics and Maternal and Child Health (DINOGMI), University of Genova, RehabilitationGenoa, Ophthalmology, Italy
| | - Alessio Mesini
- Pediatric Infectious Diseases Unit, Department of Pediatrics, IRCCS Istituto Giannina Gaslini, Genoa, Italy
| | - Jessica Tibaldi
- Emergency Room and Pediatric Emergency Medicine Unit, Emergency Department, IRCCS Istituto Giannina Gaslini, Genoa, Italy
| | - Emanuela Piccotti
- Emergency Room and Pediatric Emergency Medicine Unit, Emergency Department, IRCCS Istituto Giannina Gaslini, Genoa, Italy
| | - Luca Antonio Ramenghi
- Department of Neurosciences, Genetics and Maternal and Child Health (DINOGMI), University of Genova, RehabilitationGenoa, Ophthalmology, Italy
- Department Mother and Child, Neonatal Intensive Care Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy
| | - Andrea Moscatelli
- Neonatal and Pediatric Intensive Care Unit, and Intermediate Care Unit, Emergency Department, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genoa, Italy
| |
Collapse
|
3
|
Yuan F, Wei X, Ma X, Ma J, Ma X, Sun X, Cao M, Zhou J, Zhang W, Chen H, Wang R, Li J, Sun Q. Genetic characterizations and molecular epidemiology of human echovirus 30 isolated from Ningxia, China. BIOSAFETY AND HEALTH 2023; 5:346-354. [PMID: 40078744 PMCID: PMC11894988 DOI: 10.1016/j.bsheal.2023.10.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2023] [Revised: 09/30/2023] [Accepted: 10/09/2023] [Indexed: 03/14/2025] Open
Abstract
In October 2017, a small outbreak of echovirus 30 (E30) associated with aseptic meningitis in nine cases occurred at a primary school in the Ningxia Hui Autonomous Region. That year, we observed a significant increase in E30 levels in an acute flaccid paralysis (AFP) case surveillance system. To investigate their phylogenetic relationships, we determined the whole genomic sequences of 12 strains isolated from aseptic meningitis cases, AFP cases, and healthy children. We found that the E30 strains circulating in Ningxia belong to two lineages (H and J). The strains isolated in 2010, 2012, and 2016 belonged to the H lineage. In 2017, a new lineage, J, emerged as the dominant lineage. Phylogenetic trees were constructed based on the whole genome and P1, P2, and P3 regions; clustering with other types of enterovirus species B was found, suggesting that recombination events had occurred. The recombination sites were mainly in regions 2B, 2C, and 3D. This study confirmed that the E30 strains in Ningxia in 2010, 2012, and 2016 had different recombination patterns and were recombined with different enteroviruses. The 2017 epidemic E30 originated from another new lineage with a complex recombination pattern and formed an independent transmission chain in Ningxia.
Collapse
Affiliation(s)
- Fang Yuan
- Ningxia Hui Autonomous Region Center for Disease Control and Prevention, Yinchuan 750004, China
| | - Xinfeng Wei
- Ningxia Hui Autonomous Region People's Hospital, Yinchuan 750021, China
| | - Xueping Ma
- Ningxia Hui Autonomous Region Center for Disease Control and Prevention, Yinchuan 750004, China
| | - Jiangtao Ma
- Ningxia Hui Autonomous Region Center for Disease Control and Prevention, Yinchuan 750004, China
| | - Xuemin Ma
- Ningxia Hui Autonomous Region Center for Disease Control and Prevention, Yinchuan 750004, China
| | - Xiaoqiang Sun
- Ningxia Hui Autonomous Region Center for Disease Control and Prevention, Yinchuan 750004, China
| | - Min Cao
- Ningxia Hui Autonomous Region Center for Disease Control and Prevention, Yinchuan 750004, China
| | - Juan Zhou
- Ningxia Hui Autonomous Region Center for Disease Control and Prevention, Yinchuan 750004, China
| | - Wei Zhang
- Ningxia Hui Autonomous Region Center for Disease Control and Prevention, Yinchuan 750004, China
| | - Hui Chen
- Ningxia Hui Autonomous Region Center for Disease Control and Prevention, Yinchuan 750004, China
| | - Rui Wang
- National Laboratory for Poliomyelitis, WHO WPRO Regional Polio Reference Laboratory, National Key Laboratory for Traceability, Early Warning and Intelligent Decision of Infectious Diseases, National Health Commission Key Laboratory for Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - Jichen Li
- National Laboratory for Poliomyelitis, WHO WPRO Regional Polio Reference Laboratory, National Key Laboratory for Traceability, Early Warning and Intelligent Decision of Infectious Diseases, National Health Commission Key Laboratory for Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - Qiang Sun
- National Laboratory for Poliomyelitis, WHO WPRO Regional Polio Reference Laboratory, National Key Laboratory for Traceability, Early Warning and Intelligent Decision of Infectious Diseases, National Health Commission Key Laboratory for Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| |
Collapse
|